https://creditsmartpath.com/global-stocks-post-best-quarter-in-six-years-as-ai-boom-offsets-oil-collapse-and-yen-plunge/ 2026-06-30T16:14:27+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/financestocks.jpg https://loremflickr.com/800/400/finance,stocks https://creditsmartpath.com/accent-group-rejects-frasers-groups-a0-65-takeover-bid-as-materially-inadequate/ 2026-06-30T16:13:57+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/accent-group-rejects-frasers-groups-a0-65-takeover-bid-as-materially-inadequate_21_6ac2a.jpg https://icon.horse/icon/frasers.group https://creditsmartpath.com/biotech-ipo-revival-collides-with-big-pharmas-ma-war-chests-amid-patent-cliff-urgency/ 2026-06-30T16:02:45+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/biotech-ipo-revival-collides-with-big-pharmas-ma-war-chests-amid-patent-cliff-urgency_20_b2d83.jpg https://icon.horse/icon/nasdaq.com https://creditsmartpath.com/zealand-pharma-volatility-how-amylin-based-therapeutics-are-reshaping-the-weight-loss-market/ 2026-06-30T16:02:32+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/zealand-pharma-volatility-how-amylin-based-therapeutics-are-reshaping-the-weight-loss-market_19_49458.jpg https://icon.horse/icon/zealandpharma.com https://creditsmartpath.com/czi-biohub-escalates-biopharma-venture-new-rare-disease-funding-ai-drug-repurposing-expansion-with-every-cure/ 2026-06-30T16:02:20+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/czi-biohub-escalates-biopharma-venture-new-rare-disease-funding-ai-drug-repurposing-expansion-with-every-cure_18_782d2.jpg https://icon.horse/icon/chanzuckerberg.com https://creditsmartpath.com/medicares-july-1-obesity-drug-coverage-shift-financial-implications-for-eli-lilly-novo-nordisk-and-retirees/ 2026-06-30T16:02:03+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/medicares-july-1-obesity-drug-coverage-shift-financial-implications-for-eli-lilly-novo-nordisk-and-retirees_17_fe391.jpg https://icon.horse/icon/lilly.com https://creditsmartpath.com/medicare-greenlights-obesity-drug-coverage-a-multi-billion-dollar-windfall-for-eli-lilly-and-novo-nordisk/ 2026-06-30T16:01:51+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/medicare-greenlights-obesity-drug-coverage-a-multi-billion-dollar-windfall-for-eli-lilly-and-novo-nordisk_16_1090a.jpg https://icon.horse/icon/novonordisk.com https://creditsmartpath.com/biotech-ma-vs-ipos-how-cash-rich-big-pharma-is-reshaping-sector-valuations/ 2026-06-30T15:49:55+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/financebiotech.jpg https://loremflickr.com/800/400/finance,biotech https://creditsmartpath.com/amylin-vs-glp-1-what-zealand-pharmas-volatility-reveals-about-the-next-phase-of-the-weight-loss-market/ 2026-06-30T15:49:41+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/amylin-vs-glp-1-what-zealand-pharmas-volatility-reveals-about-the-next-phase-of-the-weight-loss-market_14_75389.jpg https://icon.horse/icon/zealandpharma.com https://creditsmartpath.com/chan-zuckerberg-biohub-expands-venture-philanthropy-new-grants-and-ai-partnerships-target-rare-disease-market/ 2026-06-30T15:49:23+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/chan-zuckerberg-biohub-expands-venture-philanthropy-new-grants-and-ai-partnerships-target-rare-disease-market_13_aac85.jpg https://icon.horse/icon/chanzuckerberg.com https://creditsmartpath.com/medicares-historic-july-1-obesity-drug-coverage-shift-what-seniors-and-investors-need-to-know/ 2026-06-30T15:49:11+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/medicares-historic-july-1-obesity-drug-coverage-shift-what-seniors-and-investors-need-to-know_12_3cf9c.jpg https://icon.horse/icon/lilly.com https://creditsmartpath.com/medicare-coverage-shift-how-novo-nordisk-and-eli-lilly-win-big-on-obesity-drug-access/ 2026-06-30T15:48:57+00:00 https://creditsmartpath.com/wp-content/uploads/2026/07/medicare-coverage-shift-how-novo-nordisk-and-eli-lilly-win-big-on-obesity-drug-access_11_b5392.jpg https://icon.horse/icon/novonordisk.com